BG
BIS icon

Bellevue Group’s ProShares UltraShort NASDAQ Biotechnology BIS Stock Holding History

Bellevue Group’s Portfolio BIS Stock Details BIS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-3,125
Closed -$426K – 214
2019
Q2 		$426K Buy
+3,125
New +$457K 0.01% 147

Other funds holding BIS

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
WP
WealthSource Partners San Luis Obispo, California $1.54B AUM 16.68% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.3B AUM 22.13% 1-Year Est. Return

Bellevue Group's BIS Position: Q3 2019 in Review

Bellevue Group sold out of ProShares UltraShort NASDAQ Biotechnology (BIS) in Q3 2019, closing a stake of 3,125 shares — an estimated $426K sold.

Bellevue Group first reported a position in BIS in Q2 2019 and held it in 1 quarter. The position peaked at $426K in Q2 2019. 9 funds tracked by Wall St. Rank hold BIS as of Q3 2019.

  • Bellevue Group reported no remaining ProShares UltraShort NASDAQ Biotechnology position as of Q3 2019 after selling out during the quarter.
  • Bellevue Group sold 3,125 ProShares UltraShort NASDAQ Biotechnology shares in Q3 2019, an estimated $426K.
  • Bellevue Group first reported a position in ProShares UltraShort NASDAQ Biotechnology in Q2 2019 and held it in 1 quarter.
  • Bellevue Group's ProShares UltraShort NASDAQ Biotechnology position peaked at $426K in Q2 2019.
  • 9 funds tracked by Wall St. Rank held ProShares UltraShort NASDAQ Biotechnology as of Q3 2019.

Based on Bellevue Group's 13F filing for Q3 2019, filed 14 Nov 2019.